NKTRNektar Therapeutics
NKTR
Nektar Therapeutics8,790
Mkt Cap
$1.97BVolume
736,184.0052W High
$77.9752W Low
$6.48PE Ratio
-6.72NKTR Fundamentals
Price
$68.66Prev Close
$70.97Open
$71.0550D MA
$59.38Beta
1.86Avg. Volume
1.76MEPS (Annual)
-$9.73P/B
15.58Rev/Employee
$876,698.41$616.46
Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting
Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of...
PR Newswire·11h ago
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar...
PR Newswire·3d ago
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Hiding Enrollment Protocol Failures: SueWallSt
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Hiding Enrollment Protocol Failures: SueWallSt NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the...
PR Newswire·3d ago
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities...
PR Newswire·3d ago
Nektar Therapeutics (NASDAQ:NKTR) Reaches New 52-Week High - Here's Why
Nektar Therapeutics (NASDAQ:NKTR) Reaches New 52-Week High - What's Next...
MarketBeat·4d ago
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: Levi & Korsinsky
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: Levi & Korsinsky...
PR Newswire·4d ago
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Overstating Trial Integrity Prospects: Levi & Korsinsky
Levi & Korsinsky, LLP alerts investors in Nektar Therapeutics (NASDAQ: NKTR) of a pending securities class action. Class Period: February 26, 2025 through December 15, 2025. Check if you can recover...
Business Wire·4d ago
Nektar Therapeutics (NASDAQ:NKTR) Coverage Initiated by Analysts at Wedbush
Wedbush began coverage on shares of Nektar Therapeutics in a research report on Tuesday. They set a "neutral" rating and a $70.00 price objective for the company...
MarketBeat·5d ago
NKTR Shareholder Alert: May 5, 2026 Lead Plaintiff Deadline in Nektar Therapeutics Securities Class Action Lawsuit -- The Gross Law Firm
NKTR Shareholder Alert: May 5, 2026 Lead Plaintiff Deadline in Nektar Therapeutics Securities Class Action Lawsuit -- The Gross Law Firm NKTR Shareholder Alert: May 5, 2026 Lead Plaintiff Deadline in...
PR Newswire·5d ago
Robbins LLP Urges NKTR Stockholders Who Lost Money Investing in Nektar Therapeutics to Contact the Firm for Information About Leading the Class Action
Robbins LLP Urges NKTR Stockholders Who Lost Money Investing in Nektar Therapeutics to Contact the Firm for Information About Leading the Class Action Robbins LLP Urges NKTR Stockholders Who Lost...
PR Newswire·5d ago
<
1
2
...
>